샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744718

교모세포종 치료제 시장

Glioblastoma Treatment Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

교모세포종 치료제 세계 시장은 2030년까지 11억 달러에 달할 전망

2024년에 8억 9,930만 달러로 추정되는 교모세포종 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 3.4%로 성장하여 2030년에는 11억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항악성종양제는 CAGR 2.8%를 기록하며 분석 기간 종료시에는 4억 8,150만 달러에 달할 것으로 예상됩니다. VEGF/VEGFR 억제제 부문의 성장률은 분석 기간 동안 CAGR 3.1%로 추정됩니다.

미국 시장은 2억 4,500만 달러로 추정, 중국은 CAGR 6.2%로 성장 예측

미국의 교모세포종 치료제 시장은 2024년에 2억 4,500만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 6.2%를 기록하며 2030년까지 2억 1,700만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.6%로 예측됩니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.

세계의 교모세포종 치료제 시장 - 주요 동향과 촉진요인 정리

교모세포종은 왜 복잡하면서도 암 영역에서 시급히 해결해야 할 타겟이 될 수 있을까?

다형성교모세포종(GBM)은 가장 공격적이고 치명적인 뇌종양 중 하나이며, 빠른 진행, 치료 저항성, 낮은 환자 생존율이 특징입니다. 교모세포종은 침습성이 높고 유전적으로 불균일하기 때문에 수술적 절제, 방사선 치료, 화학요법 등 표준 치료는 부분적으로만 효과가 있습니다. 현재 1차 치료는 방사선 치료와 함께 테모졸로미드를 병용하는 경우가 많지만 재발은 거의 피할 수 없습니다. 약물의 투과성을 제한하는 혈액뇌장벽(BBB)은 약리학적 개입을 더욱 복잡하게 만들어 효과적인 약물 치료의 개발을 특히 어렵게 만들고 있습니다.

이러한 장애에도 불구하고 GBM은 임상적 심각성과 근본적인 치료법의 부족으로 인해 종양학 약물 개발의 우선순위가 높은 분야입니다. 분자생물학 및 유전체학의 발전으로 EGFR 증폭, IDH 돌연변이, MGMT 메틸화, PD-L1 발현 등 몇 가지 표적이 될 수 있는 돌연변이 및 바이오마커가 확인되어 현재 정밀 치료 전략의 지침이 되고 있습니다. 미충족 의료 수요와 희귀질환 치료제(희귀의약품)에 대한 규제적 특혜가 맞물리면서, 현재 치료법의 한계를 극복하기 위한 새로운 치료법을 개발하려는 생명공학 기업 및 제약 혁신가들의 수가 증가하고 있습니다.

새로운 치료법과 약제 종류별로 GBM 치료 옵션을 어떻게 재구성하고 있는가?

혁신의 물결이 GBM 치료제의 상황을 바꾸고 있으며, 여러 가지 새로운 치료제가 임상 개발에 진입하고 있습니다. 비정상적인 신호전달 경로(EGFR, VEGF, PI3K/ACT/mTOR 등)를 표적으로 하는 표적 치료제가 인기를 끌고 있으며, 대부분 단독요법에서 다양한 효능을 보이고 있습니다. 적응증 저항성을 극복하기 위해 표적 억제제와 방사선 요법이나 면역관문억제제와의 병용요법이 조사되고 있습니다. 면역요법, 특히 면역관문억제제(PD-1/PD-L1 억제제 등), 종양용해성 바이러스, 수지상세포 백신 등은 면역이 부족한 종양 미세환경에서 항종양 면역을 자극할 수 있는 가능성이 검토되고 있습니다.

유전자 치료와 종양 치료 영역(TTF)도 치료 포트폴리오의 중요한 요소가 되고 있습니다. 일부 시장에서 승인된 비침습적 치료법인 TTF는 교대 전기장을 통해 유사분열을 파괴하는 치료법으로, 종종 화학요법과 함께 사용됩니다. 한편, CRISPR 및 siRNA 플랫폼과 같은 유전자 편집 기술은 발암 유발인자를 침묵시키고 종양 억제 기능을 회복시키기 위해 활용되고 있습니다. 또한, 나노 캐리어 기반 약물전달 시스템의 발전은 BBB를 우회하여 세포독성 약물이나 유전자 변형 약물을 종양 부위에 직접 전달함으로써 전신 독성을 줄이면서 치료 효과를 높일 수 있다는 점에서 유망한 것으로 평가받고 있습니다. 이러한 새로운 접근법은 어려운 임상적 과제에도 불구하고 교모세포종 치료의 가능성을 재정의하고 있습니다.

이 시장에서 혁신과 상업적 전략을 형성하는 트렌드는 무엇인가?

몇 가지 거시적 및 과학적 동향이 교모세포종 치료제 시장의 혁신 궤적과 상업적 역학에 영향을 미치고 있습니다. 가장 주목할 만한 트렌드는 분자 프로파일을 기반으로 환자 집단을 계층화하여 보다 표적화되고 잠재적으로 효과적인 치료를 가능하게 하는 바이오마커 기반 임상시험에 대한 의존도가 높아지고 있다는 점입니다. 액체 생검과 차세대 염기서열 분석기는 실용적인 돌연변이 식별과 치료 반응 모니터링에 자주 사용되고 있습니다. 규제 당국은 혁신과 시장 진입을 촉진하기 위해 패스트트랙, 혁신치료제, 희귀질환 치료제 지정과 같은 신속한 경로를 제공하고 있으며, 특히 초기 단계의 유망한 치료제에 대해 규제 당국은 이를 지원하고 있습니다.

벤처 캐피털 및 제약사와의 제휴는 초기 단계의 혁신, 특히 면역치료제 및 유전자 편집 플랫폼을 개발하는 기업들에게 초기 단계의 혁신에 자금을 공급하는 데 있어 중요한 역할을 하고 있습니다. 산학협력이 발전함에 따라 보다 신속한 중개연구와 임상시험 인프라에 대한 접근이 가능해지고 있습니다. 또한, 가격 책정 및 상환 전략은 희귀암에 대한 고비용 치료에 대응할 수 있도록 진화하고 있으며, 실제 임상 결과와 생존 혜택을 입증하는 데 초점을 맞추고 있습니다. 지불자는 시장 진입을 위한 가정으로 바이오마커로 뒷받침되는 가치 제안과 동반진단 약물을 요구하기 시작했으며, 이는 제약사들이 보다 통합적인 개발 전략을 채택하도록 영향을 미치고 있습니다.

교모세포종 치료제 시장의 성장 원동력은?

교모세포종 치료제 시장의 성장은 치료법의 발전, 환자 계층화, 임상 파이프라인의 확장과 직접적으로 연관된 여러 요인에 의해 주도되고 있습니다. 정밀 종양학(Precision Oncology) 도구의 등장으로 종양 아형에 대한 보다 효과적인 타겟팅이 가능해져 틈새 환자군의 반응률 향상과 생존기간 연장이 가능해짐에 따라 CAR-T 세포 치료, 신항원 백신, 종양용해성 바이러스 플랫폼과 같은 면역요법에 대한 지속적인 투자는 치료 저항성 또는 재발성 GBM 환자들을 위한 새로운 지평을 열어가고 있습니다. 또한, 테모졸로미드, 방사선 요법, 신규 약물을 포함한 병용요법의 사용이 확대되면서 임상 결과가 개선되고 새로운 표준 치료법이 확립되고 있습니다.

희귀질환 치료제(희귀의약품) 개발에 대한 규제 혜택과 조기 승인 경로를 통해 유망한 치료제, 특히 분자 시그니처를 표적으로 하는 치료제와 BBB를 관통하는 혁신적인 전달 시스템을 채택한 치료제의 시장 출시 시간이 단축되고 있습니다. 이와 함께 디지털 영상, AI 기반 치료 계획, 바이오마커 분석의 부상으로 임상시험 설계, 환자 선택, 치료 모니터링이 강화되고 있습니다. 교모세포종 진단의 유병률 증가는 인구의 고령화와 신경 영상 기술의 발전으로 인해 환자 기반이 더욱 확대되고 있습니다. 이러한 기술적, 규제적, 임상적 발전이 결합되어 성장을 촉진하고 종양학에서 가장 어려운 과제 중 하나인 효과적인 약물 요법 개발에 대한 노력을 촉진하고 있습니다.

부문

약물 종류별(항악성종양제, VEGF/VEGFR 억제제, 알킬화제, 기타 항악성종양제), 유통 채널별(병원, 암 연구 기관, 장기간병 센터, 진단 센터, 기타 유통 채널)

조사 대상 기업 사례(총 41개사)

  • Amgen Inc.
  • Ariceum Therapeutics
  • Bristol-Myers Squibb
  • CNS Pharmaceuticals
  • Epitopoietic Research Corporation
  • ImmunityBio, Inc.
  • Medivir AB
  • Merck & Co., Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pacific Marine Biotech
  • Pfizer Inc.
  • Roche Holding AG
  • SOM Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Telix Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • TME Pharma AG
  • TransMolecular, Inc.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.06.20

Global Glioblastoma Treatment Drugs Market to Reach US$1.1 Billion by 2030

The global market for Glioblastoma Treatment Drugs estimated at US$899.3 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Antineoplastic, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$481.5 Million by the end of the analysis period. Growth in the VEGF / VEGFR Inhibitors segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$245.0 Million While China is Forecast to Grow at 6.2% CAGR

The Glioblastoma Treatment Drugs market in the U.S. is estimated at US$245.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$217.0 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Glioblastoma Treatment Drugs Market - Key Trends & Drivers Summarized

Why Is Glioblastoma a Complex Yet Urgently Addressed Target in Oncology?

Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal forms of brain cancer, characterized by rapid progression, treatment resistance, and poor patient survival rates. The highly infiltrative nature of glioblastoma and its genetic heterogeneity make standard treatments such as surgical resection, radiotherapy, and chemotherapy only partially effective. Current first-line therapy often includes temozolomide in combination with radiotherapy, yet recurrence is almost inevitable. The blood-brain barrier (BBB), which limits drug permeability, further complicates pharmacological intervention, making the development of effective drug treatments particularly challenging.

Despite these obstacles, GBM has become a high-priority area in oncology drug development due to its clinical severity and the lack of curative therapies. Advances in molecular biology and genomics have identified several targetable mutations and biomarkers-such as EGFR amplification, IDH mutations, MGMT methylation, and PD-L1 expression-that are now guiding precision treatment strategies. The unmet medical need, coupled with regulatory incentives for orphan drugs, is attracting a growing number of biotech firms and pharmaceutical innovators to develop novel therapeutic approaches aimed at overcoming the limitations of current treatments.

How Are New Modalities and Drug Classes Reshaping GBM Treatment Options?

A wave of innovation is transforming the GBM treatment drug landscape, with several new classes of therapeutics entering clinical development. Targeted therapies aimed at aberrant signaling pathways (such as EGFR, VEGF, and PI3K/AKT/mTOR) are gaining traction, although many have shown mixed efficacy in monotherapy. Combination approaches, such as pairing targeted inhibitors with radiation or immune checkpoint inhibitors, are under intense investigation to overcome adaptive resistance. Immunotherapy, particularly immune checkpoint blockade (e.g., PD-1/PD-L1 inhibitors), oncolytic viruses, and dendritic cell vaccines, is being explored for its potential to stimulate anti-tumor immunity in an otherwise immune-cold tumor microenvironment.

Gene therapy and tumor-treating fields (TTF) are also becoming critical elements of the therapeutic portfolio. TTF, a non-invasive modality approved in several markets, disrupts mitosis through alternating electric fields and is often used in conjunction with chemotherapy. Meanwhile, gene-editing technologies such as CRISPR and siRNA platforms are being harnessed to silence oncogenic drivers and restore tumor suppressor function. Moreover, advancements in nanocarrier-based drug delivery systems are showing promise in bypassing the BBB and delivering cytotoxic or gene-modifying agents directly to tumor sites, thereby increasing therapeutic efficacy while reducing systemic toxicity. These novel approaches are redefining what is possible in glioblastoma care, despite the daunting clinical challenges.

What Trends Are Shaping Innovation and Commercial Strategy in This Market?

Several macro and scientific trends are influencing both the innovation trajectory and commercial dynamics of the glioblastoma treatment drug market. A notable trend is the increasing reliance on biomarker-driven clinical trials that stratify patient populations based on molecular profiles, allowing for more targeted and potentially effective therapies. Liquid biopsy and next-generation sequencing are being used more frequently to identify actionable mutations and monitor treatment response. Regulatory bodies are offering expedited pathways such as Fast Track, Breakthrough Therapy, and Orphan Drug Designation to encourage innovation and market entry, particularly for treatments showing promise in early-phase trials.

Venture capital and pharmaceutical partnerships are playing a crucial role in financing early-stage innovation, especially for companies developing immunotherapies and gene-editing platforms. Academic-industry collaborations are increasing, leading to faster translational research and access to clinical trial infrastructure. Furthermore, pricing and reimbursement strategies are evolving to accommodate high-cost therapies for rare cancers, with a focus on demonstrating real-world outcomes and survival benefits. Payers are beginning to demand biomarker-supported value propositions and companion diagnostics as prerequisites for market access, which is influencing drug developers to adopt more integrated development strategies.

What Is Driving Growth Across the Glioblastoma Treatment Drugs Market?

The growth in the glioblastoma treatment drugs market is driven by several factors directly tied to advances in therapy modalities, patient stratification, and the expanding clinical pipeline. The emergence of precision oncology tools is enabling more effective targeting of tumor subtypes, improving response rates and extending survival in niche patient groups. Ongoing investment in immunotherapies-including CAR-T cell therapy, neoantigen vaccines, and oncolytic viral platforms-is creating new frontiers for treatment-resistant or recurrent GBM cases. Additionally, the expanding use of combination regimens involving temozolomide, radiotherapy, and novel agents is improving clinical outcomes and setting new standards of care.

Regulatory incentives for orphan drug development and accelerated approval pathways are reducing time-to-market for promising treatments, especially those targeting molecular signatures or employing innovative delivery systems to penetrate the BBB. In parallel, the rise of digital imaging, AI-based treatment planning, and biomarker analytics is enhancing clinical trial design, patient selection, and therapy monitoring. The increasing prevalence of glioblastoma diagnoses, driven in part by aging populations and improved neuroimaging, is further expanding the patient base. Collectively, these technological, regulatory, and clinical advancements are fueling growth and revitalizing efforts to develop effective drug therapies for one of the most difficult challenges in oncology.

SCOPE OF STUDY:

The report analyzes the Glioblastoma Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents, Miscellaneous Antineoplastic); Distribution Channel (Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Amgen Inc.
  • Ariceum Therapeutics
  • Bristol-Myers Squibb
  • CNS Pharmaceuticals
  • Epitopoietic Research Corporation
  • ImmunityBio, Inc.
  • Medivir AB
  • Merck & Co., Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pacific Marine Biotech
  • Pfizer Inc.
  • Roche Holding AG
  • SOM Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Telix Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • TME Pharma AG
  • TransMolecular, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Glioblastoma Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Glioblastoma Multiforme Drives Urgent Demand for Novel Therapeutic Agents
    • Limited Efficacy of Standard Therapies Strengthens the Case for Targeted and Personalized Drug Development
    • Expansion of Genomic and Molecular Profiling Capabilities Accelerates Adoption of Precision Oncology Treatments
    • Increased Investment in Immuno-Oncology Spurs Growth of Checkpoint Inhibitors and CAR-T Cell Therapies for Glioblastoma
    • High Recurrence Rates Propel Interest in Combination Therapies and Maintenance Treatment Regimens
    • FDA Fast-Track and Orphan Drug Designations Stimulate Innovation in Experimental Glioblastoma Treatments
    • Rising Focus on Blood-Brain Barrier Penetration Challenges Drives Development of Nanocarrier and Liposomal Drug Platforms
    • Advancements in RNA-Based Therapeutics and Gene Editing Technologies Expand the Pipeline of Disruptive Drug Candidates
    • Growing Application of Artificial Intelligence in Drug Discovery Shortens Development Cycles for Glioblastoma Candidates
    • Limited Success of Traditional Chemoradiation Regimens Creates Market Openings for Adaptive and Precision Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glioblastoma Treatment Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glioblastoma Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antineoplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for VEGF / VEGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for VEGF / VEGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for VEGF / VEGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Miscellaneous Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Miscellaneous Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Miscellaneous Antineoplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cancer Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Long Term Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Long Term Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Long Term Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Glioblastoma Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제